CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

SAMPLE ID:	PRODUCT NAME:	
Strength:		
Lot Number:		
Expiration Date:		
CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
THCV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Sample Size		
THC by Mass		
HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		

Lead

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	
RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

- 1. The hemp extract is the product of a batch tested by the independent testing laboratory;
- 2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
- 3. The batch does not contain contaminants unsafe for human consumption.

 † Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.



September 20, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391

Lot Number A107360924

Category (Type) Non-Inhalable Edible (Capsule)

Received September 20, 2024

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant) Pass

tested.

Instrument Liquid Chromatography Diode Array Detector (LC-DAD)

Method MF-CHEM-15

Analysis Date September 20, 2024

Cannabinoid	mg/g	%	mg/serving	mg/package	Labeled mg/ serving	% Difference (mg/ serving)	Status
Δ8-ΤΗС	ND	ND	ND	ND	-	-	-
Δ9-ΤΗС	ND	ND	ND	ND	-	-	Pass
Δ9-ΤΗCΑ	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	-	-	-
CBD	84.98	8.498	53.86	3231.8	50	7.73	-
CBDA	ND	ND	ND	ND	-	-	-
CBC	2.35	0.235	1.49	89.30	-	-	-
CBCA	ND	ND	ND	ND	-	-	-
CBDV	1.48	0.148	0.94	56.38	-	-	-
CBG	1.95	0.195	1.24	74.17	-	-	-
CBGA	ND	ND	ND	ND	-	-	-
CBN	2.80	0.280	1.78	106.60	-	-	-
Total THC	ND	ND	ND	ND	-	-	-
Total CBD	84.98	8.498	53.86	3231.8	-	-	-
Total Cannabinoids	93.57	9.357	59.30	3558.26	-	-	-
Sum of Cannabinoids	93.57	9.357	59.30	3558.26	-	-	-
Serving Weight (g)	0.6338						
Package Weight (g)	38.03						

Reported results and measurements are based off of a calculated hypothetical weight using the ratio between filling weight and total capsule weight as per client instruction. Only the filling material was

Reported by **Anresco, Inc.**

Comments

Ali Sweeney
Analyst II

September 20, 2024

ND = None Detected LOD = Limit of Detection ($0.1333 \, mg/g$) LOQ = Limit of Quantitation ($0.4000 \, mg/g$) Total THC = $\Delta 8$ -THC + $\Delta 9$ -THC + ($0.877 \, ^*$ THCA) Total CBD = CBD + ($0.877 \, ^*$ CBDA) Total Cannabinoids = Σ (neutral cannabinoids) + [$0.877 \, ^*$ Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **1** Report ID: T-2



September 24, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391

Lot Number A107360924

Category (Type) Non-Inhalable Edible (Capsule)

Received September 20, 2024

ANALYTICAL RESULTS

Analysis Pesticide Screen Pass

Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem

Mass Spectrometry (GC-MS/MS)

Method MF-CHEM-13

Analysis Date September 20, 2024 to September 24, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **2** Report ID: T-2



Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by **Anresco, Inc.**



September 24, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Sample #: 1245256

Batch #: A107360924



September 24, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391

Lot Number A107360924

Category (Type) Non-Inhalable Edible (Capsule)

Received September 20, 2024

ANALYTICAL RESULTS

Analysis Residual Solvent Screen Pass

Instrument Gas Chromatography Mass Spectrometry (GC/MS)

Method MF-CHEM-32

Analysis Date September 20, 2024 to September 24, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by **Anresco, Inc.**

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation



September 24, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **1** Report ID: T-2



September 24, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391

Lot Number A107360924

Category (Type) Non-Inhalable Edible (Capsule)

Received September 20, 2024

ANALYTICAL RESULTS

Analysis Mycotoxins Screen Pass

Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem

Mass Spectrometry (GC-MS/MS)

Method MF-CHEM-13

Analysis Date September 20, 2024 to September 24, 2024

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by

Anresco, Inc.

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation



September 24, 2024

If there are any questions with this report, please contact "compliance@anresco.com".



USP <62>

September 26, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391

Lot Number A107360924

Received September 20, 2024

ANALYTICAL RESULTS

Analysis Date September 20, 2024 to September 26, 2024

Staph aureus

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /10g	MF-MICRO-11 (AOAC 2016.01)

Negative /10g

Reported by **Anresco, Inc.**



If there are any questions with this report, please contact "compliance@anresco.com".



September 24, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 561187 Sample No. 1245256

SAMPLE INFORMATION

Description FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391

Lot Number A107360924

Category (Type) Non-Inhalable Edible (Capsule)

Received September 20, 2024

ANALYTICAL RESULTS

Analysis Heavy Metals **⊘** Pass

Instrument Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

Method MF-CHEM-16

Analysis Date September 20, 2024 to September 24, 2024

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.125	<loq< th=""><th>0.5</th><th>Pass</th></loq<>	0.5	Pass

Reported by **Anresco, Inc.**

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

Eric Tam Senior Chemist

September 24, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate Of Completion

Envelope Id: E514B1577655432F8A84AB0075FE9C5F

Subject: FP-24-0089 PlusCBD 50mg 60ct Softgels exp 08/26 SKU 391 A107360924

Source Envelope:

Document Pages: 9 Signatures: 1 Certificate Pages: 1 Initials: 0 Vandana Kothari

AutoNav: Enabled

Envelopeld Stamping: Enabled

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Envelope Originator:

Status: Completed

vandana.kothari@cvsciences.com IP Address: 64.207.219.135

Record Tracking

Status: Original

9/27/2024 11:07:17 AM

Holder: Vandana Kothari

vandana.kothari@cvsciences.com

Location: DocuSign

Sent: 9/27/2024 11:07:55 AM

Viewed: 9/27/2024 11:08:52 AM

Signed: 9/27/2024 11:09:25 AM

Timestamp

Signer Events

Vandana Kothari

vandana.kothari@cvsciences.com

DIRECTOR OF QUALITY

CV Sciences - Part 11

Security Level: Email, Account Authentication

(Required)

Signature

Vandana kothani

Signature Adoption: Pre-selected Style

Signature ID:

87A410FF-F032-4873-8900-BEED0868E359

Using IP Address: 75.85.176.253

With Signing Authentication via DocuSign password

With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure:

Not Offered via DocuSign

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	9/27/2024 11:07:55 AM
Certified Delivered	Security Checked	9/27/2024 11:08:52 AM
Signing Complete	Security Checked	9/27/2024 11:09:25 AM
Completed	Security Checked	9/27/2024 11:09:25 AM
Payment Events	Status	Timestamps